Overcoming Racial Disparities in Screening Mammography

August 9, 2026 updated by: Washington University School of Medicine

A Personalized Approach to Promote Health Equity by Overcoming Racial Disparities in Screening Mammography

The purpose of this study is to increase screening mammography among Black women by implementing and evaluating a culturally tailored patient-centric program designed to address barriers to screening. By performing a randomized clinical trial, this study aims to develop effective strategies to improve adherence to screening mammography and contribute to reducing health disparities in breast cancer outcomes.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

176

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Missouri
      • St Louis, Missouri, United States, 63110
        • Washington University School of Medicine
        • Contact:
        • Principal Investigator:
          • Foluso Ademuyiwa, MD, MPH, MSCI
        • Sub-Investigator:
          • Debbie Bennett, MD
        • Sub-Investigator:
          • Ashley Housten, OTD, OTR, MSCI, MPA
        • Sub-Investigator:
          • Ying Liu, MD, PhD
        • Sub-Investigator:
          • Shaili Tapiavala, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Woman
  • At least 40 years old
  • Self-identify as Black
  • English-speaking
  • Scheduled for a screening mammogram within 8 weeks of study entry
  • Able to understand and willing to sign an IRB approved written informed consent document.

Exclusion Criteria:

  • A previous history of breast cancer
  • Scheduled for a diagnostic mammogram
  • Has a documented or uncorrectable cognitive, hearing, or visual impairment.
  • Too ill to participate (diagnosed with or suffering from a condition that, in the judgment of the investigator, may limit participation in the study).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Arm 1: Usual Care
Patients will receive the institution's usual care for screening mammogram, which consists of an automated reminder phone call from the breast health center 1-3 days prior to a scheduled appointment.
Other: Automated phone call
Patient will receive an automated reminder phone call for their appointment 1-3 days prior to the appointment.
Experimental: Arm 2: Culturally Tailored Patient Centric Program Methods
Patients will receive mail reminders at 7-10 days prior to appointment, tailored telephone counseling to both serve as an appointment reminder and to identify and troubleshoot salient barriers to mammography completion, and a digital navigation video explaining the rationale for and the actual mammography procedure. All study procedures are carried out remotely with no additional research visits for participants.
Other: Appointment mail reminder
Patient will receive an appointment reminder in the mail 7-10 days prior to the appointment.
Other: Telephone counseling
The telephone counseling will include an appointment reminder within 7 days of their appointment and identify and troubleshoot barriers to patient's mammography completion.
Other: Digital navigation video
The digital navigation video will explain the rationale for the mammogram and the mammography procedure. Digital navigation video will be sent by SMS text message 1-3 days prior to the appointment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
No-show rate
Time Frame: 6 months after randomization
Defined as the proportion of participants who do not complete (or do not reschedule) their screening mammogram appointment within 6 months of randomization.
6 months after randomization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Washington University School of Medicine

Collaborators

Novartis
National Comprehensive Cancer Network

Investigators

  • Principal Investigator: Foluso Ademuyiwa, MD, MPH, MSCI, Washington University School of Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 31, 2026

Primary Completion (Estimated)

April 30, 2028

Study Completion (Estimated)

April 30, 2028

Study Registration Dates

First Submitted

April 17, 2026

First Submitted That Met QC Criteria

April 17, 2026

First Posted (Actual)

April 23, 2026

Study Record Updates

Last Update Posted (Actual)

August 12, 2026

Last Update Submitted That Met QC Criteria

August 9, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 202604048

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe